Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors

Federica Sora', Simona Sica, Massimo Breccia, Fabio Stagno, Antonella Gozzini, Elisabetta Abruzzese, Roberto Latagliata, Antonella Russo Rossi, Raffaele Porrini, Paolo Vigneri, Malgorzata Trawinska, Enrico Montefusco, Giorgina Specchia, Valeria Santini, Giuliana Alimena

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

In this study, we confirm the validity of the proposed Hammersmith score, which identifies three risk categories of patients and establish its strength on a large group of 128 chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors (TKIs) after being resistant to imatinib. Sixty-one patients were identified as good risk group, 27 patients as intermediate risk group, and 40 patients as poor risk group. The 1-year cumulative incidence of complete cytogenetic response was 73% in good risk patients, 40% in intermediate risk patients, and 22% in poor risk patients (P = 0.0001). Event-free survival at 3-year was 89% in good risk group, 70% in intermediate group, and 54% in poor risk group (P = 0.0001); the estimated 3-year progression-free survival was 95% in good risk category, 93% in intermediate risk category, and 87% in poor risk category (P = 0.05). Kaplan–Meier estimated that the 3-year overall survival was 100% in good risk category, 93% in intermediate risk category, and 82% in poor risk category (P = 0.04). In conclusion, some prognostic factors before starting second-generation TKIs might predict cytogenetic response and outcome. The so-called Hammersmith score was not yet validated in large series of patients: we demonstrated that this score is able to discriminate patients at high risk of failure and consequent progression before treatment with second-generation TKIs.
Lingua originaleEnglish
pagine (da-a)523-525
Numero di pagine3
RivistaAmerican Journal of Hematology
Volume86
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Female
  • Humans
  • Italy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prognosis
  • Protein Kinase Inhibitors
  • Risk Assessment
  • Survival Analysis

Fingerprint

Entra nei temi di ricerca di 'Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors'. Insieme formano una fingerprint unica.

Cita questo